Obesity’s impact on metabolic syndrome clusters andfatty liver incidence in millennial subjects

Winnie Pratiwi Achmad; Himawan Sanusi; Andi Muhammad Luthfi  Parewangi; Syakib Bakri; Harun  Iskandar; Arifin Seweng

doi:10.23750/abm.v95i2.15323

Obesity’s impact on metabolic syndrome clusters andfatty liver incidence in millennial subjects

Authors

Winnie Pratiwi Achmad Universitas Hasanuddin
Himawan Sanusi Department of Internal Medicine, Faculty Of Medicine, Hasanuddin University
Andi Muhammad Luthfi Parewangi Department of Internal Medicine, Faculty Of Medicine, Hasanuddin University
Syakib Bakri Department of Internal Medicine, Faculty Of Medicine, Hasanuddin University
Harun Iskandar Department of Internal Medicine, Faculty Of Medicine, Hasanuddin University
Arifin Seweng Department of Public Health and Community Medicine, Faculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia

DOI: https://doi.org/10.23750/abm.v95i2.15323

Keywords:

fatty liver, central obesity, general obesity, metabolic syndrome

Abstract

Background and Aim:The expanding mass of adipose tissue amplifies the release of free fatty acids, leading to insulin resistance and the onset of metabolic syndrome. In addition to obesity, metabolic syndrome encompasses four other key components. Metabolic Associated Fatty Liver Disease (MAFLD) is a condition characterized by fatty liver occurring in conjunction with metabolic syndrome. However, research into the influence of obesity within metabolic syndrome on the development of fatty liver, particularly in Indonesia, remains limited. This study seeks to elucidate the impact of obesity on the clustering of metabolic syndrome components in millennials and its role in the development of fatty liver. Methods:This cross-sectional study enlisted 91 subjects, subjecting them to screening for metabolic syndrome components and fibroscan examinations to evaluate fatty liver. Statistical analysis encompassed the chi-squared test and multivariate analysis using multiple logistic regression. Results:Among the metabolic syndrome components, obesity emerged as the most significant factor associated with fatty liver (P: 0.002; OR 4.7; 95% CI 1.76–12.70). The obese group with metabolic syndrome exhibited a significantly higher incidence of fatty liver (75.0%; P:< 0.001) compared to the non-obese group (69.8%). In an analysis comparing central obesity with general obesity, it was revealed that general obesity bore a more substantial relationship with the development of fatty liver than central obesity (P: 0.003 vs. 0.102). Conclusions:Obesity represents a substantial risk factor for fatty liver development, especially when combined with metabolic syndrome. Furthermore, general obesity exhibits a more pronounced association with the degree of fatty liver compared to central obesity.

References

Gastaldelli A. Fatty liver disease: The hepatic manifestation of metabolic syndrome. Hypertens Res. 2010;33(6):546–7. doi:10.1038/hr.2010.60.

Dobrowolski P, Prejbisz A, Kurylowicz A, et al. Metabolic syndrome a new definition and management guidelines. Arch Med Sci. 2022;18(5):1133–56. doi:10.5114/aoms/152921.

Tang SY, Tan JS, Pang XZ, Lee GH. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact. World J Gastroenterol. 2023;29(3):549–60. doi:10.3748/wjg.v29.i3.549.

Chang WP, Chang YP. Correlation between Component Factors of Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Nurses: An Observational and Cross-Sectional Study. Int J Environ Res Public Health. 2022;19(23). doi:10.3390/ijerph192316294.

Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: From obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr [Internet]. 2020;12(1):1–20. doi:10.1186/ bs13098-020-00570-y.

Moy FM, Bulgiba A. The modified NCEP ATP III criteria maybe better than the IDF criteria in diagnosing Metabolic Syndrome among Malays in Kuala Lumpur. BMC Public Health. 2010;10:2–7. doi:10.1186/1471-2458-10-678.

Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017;11(8):215–25. doi: 10.1177/1753944717711379.

Almeda-Valdes P, Cuevas-Ramos D, Aguilar-Salinas CA. Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol. 2009;8(SUPPL. 1):18–24. doi:10.1016/s1665-2681(19)31822-8.

Goyal A, Hobinder A, Arora S. Prevalence of fatty liver in metabolic syndrome. J Fam Med Prim Care [Internet]. 2020;9(2):3246–50. doi:10.4103/jfmpc.jfmpc.

Bhargav V, Jain M, Alen T, et al. Clusters and components of metabolic syndrome (MeS) as a predictor for fatty liver: A cross-sectional study. J Diabetol. 2021;12(4):434. doi:10.4103/ jod.jod_17_21.

Johanson LS. Caring for Patients of the Millennial Generation: Considerations for Nurses. Nurs Forum. 2017;52(3):207–10. doi: 10.1111/nuf.12190.

Pang Q, Zhang JY, Song SD, et al. Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index. World J Gastroenterol. 2015;21(5):1650–62. doi:10.3748/wjg.v21.i5.1650.

Zarghamravanbakhsh P, Frenkel M, Poretsky L. Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). Metab Open [Internet]. 2021;12:100149. doi:10.1016/ j.metop.2021.100149.

Li AA, Ahmed A, Kim D. Extrahepatic manifestations of nonalcoholic fatty liver disease. Gut Liver. 2020;14(2):168–78. doi:10.5009/gnl19069.

Drożdż K, Nabrdalik K, Hajzler W, Kwiendacz H, Gumprecht J, Lip GYH. Metabolic-associated fatty liver disease (MAFLD), diabetes, and cardiovascular disease: Associations with fructose metabolism and gut microbiota. Nutrients. 2022;14(1). doi:10.3390/ nu14010103.

Tomizawa M, Kawanabe Y, Shinozaki F, et al. Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. Biomed Reports. 2014;2(5):633–6. doi:10.3892/br.2014.309.

Yuan Q, Wang H, Gao P, et al. Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease among 73,566 Individuals in Beijing, China. Int J Environ Res Public Health. 2022;19(4). doi:10.3390/ijerph19042096.

Zakerkish M, Assarzadeh A, Seyedian SS, Jahanshahi A. Prevalence of Metabolic Syndrome and Related Factors in Patients with Non-alcoholic Fatty Liver. Jundishapur J Chronic Dis Care. 2021;11(1):1–8. doi:10.5812/jjcdc.114541.

Rafique T, Zeba Z, Zinnat R, Ali L. Core Components of the Metabolic Syndrome in Nonalcohlic Fatty Liver Disease. IOSR J Biotechnol Biochem [Internet]. 2015;1(2):21–5. Available from: www.iosrjournals.org.

Chakravarthy MV, Neuschwander-Tetri BA. The metabolic basis of nonalcoholic steatohepatitis. Endocrinol Diabetes Metab. 2020;3(4):1–13. doi:10.1002/edm2.112.

Ratnasari N, Senorita H, Adie RH, Bayupurnama P, Maduseno S, Nurdjanah S. Non- alcoholic Fatty Liver Disease Related to Metabolic Syndrome : a Case- control Study. Indones J Gastroenterol Hepatol Dig Endosc. 2012;13(1):8–13. doi:10.24871/13120128-13.

Tateda T, Iino C, Sasada T, et al. Evaluation of metabolic dysfunction-associated fatty liver disease using FibroScan, diet, and microbiota: A large cross-sectional study. PLoS One. 2022;17(11 November):1–17. doi:10.1371/journal.pone.0277930.